Key Highlights

  • Lumos Diagnostics shares traded up 8.57% at $0.076 during the 11 November 2026 trading session.
  • WellStreet Urgent Care will expand standardised adoption of FebriDx across more than 200 locations.
  • The rollout is set to bring the number of US sites using FebriDx to 365 once implemented.

During the Trading session on 11 November 2026, Lumos Diagnostics Holdings Ltd (ASX:LDX) shares were trading at $0.076 by late morning, up 8.57%. The S&P/ASX 200 (ASX:XJO) was down about 0.06% at 9,123.90 at 12:19 pm over the same period. Lumos is a Melbourne-based developer of rapid point-of-care diagnostic tests. On 9 November 2026, the company announced that WellStreet Urgent Care would expand its adoption of the FebriDx test across its network.

 

WellStreet Rollout of FebriDx

On 9 November 2026, Lumos announced that WellStreet Urgent Care, the sixth largest urgent care network in the United States, will roll out FebriDx to an additional 97 locations. Under WellStreet’s protocol, the test will be offered to patients presenting with acute respiratory infection symptoms, which WellStreet estimates account for 70% to 80% of patient visits during cold and flu season. The network represents more than one million acute respiratory presentations a year.

 

Path to Full Network Adoption

The company said it expects the expansion to cover all WellStreet locations, more than 200 in total, across all markets by 31 December 2026. Once implemented, the rollout will bring the number of US sites using FebriDx to 365. The adoption follows a single-site pilot agreement that Lumos entered into with WellStreet in October 2025, which was linked to WellStreet’s joint venture with Piedmont Healthcare in Atlanta, Georgia.

 

Testing Pathway and Reimbursement

FebriDx is a rapid point-of-care test that uses a fingerstick blood sample to help differentiate between bacterial and non-bacterial infection. The announcement linked the wider adoption to the pilot’s success in advancing testing and reimbursement pathways for the product in the US.

 

Sector Context

Point-of-care diagnostics are attracting attention in the United States as urgent care providers look for rapid tools to guide treatment decisions. Adoption by large networks is often a key step for small diagnostics companies, and shares in the sector can respond to Partnership and rollout news.

 

Key Risks

The expansion depends on WellStreet completing its planned rollout, and timing across more than 200 locations may vary. Adoption at the network level does not by itself guarantee broader revenue, and reimbursement arrangements can affect uptake. Lumos is also a small-cap company with a low share price, where moves can be volatile.

 

What to Watch Ahead

The main milestone to follow is the completion of the WellStreet rollout across all locations by 31 December 2026. Investors will also look for further updates on additional US networks and on the reimbursement pathway for FebriDx in the coming months.

 

Final Word

The share price movement on 11 November 2026 came as Lumos continues to build its US footprint for FebriDx. The pace of the WellStreet rollout will indicate how quickly the wider network adoption develops.